257 related articles for article (PubMed ID: 22403285)
1. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets.
Pastuszak AW; Mittakanti H; Liu JS; Gomez L; Lipshultz LI; Khera M
J Androl; 2012; 33(5):927-37. PubMed ID: 22403285
[TBL] [Abstract][Full Text] [Related]
2. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous implantable testosterone pellets overcome noncompliance in adolescents with Klinefelter syndrome.
Moskovic DJ; Freundlich RE; Yazdani P; Lipshultz LI; Khera M
J Androl; 2012; 33(4):570-3. PubMed ID: 21940986
[TBL] [Abstract][Full Text] [Related]
4. Coadministration of anastrozole sustains therapeutic testosterone levels in hypogonadal men undergoing testosterone pellet insertion.
Mechlin CW; Frankel J; McCullough A
J Sex Med; 2014 Jan; 11(1):254-61. PubMed ID: 24119010
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for Treatment of Symptoms Associated With Androgen Deficiency.
McMahon CG; Shusterman N; Cohen B
J Sex Med; 2017 Jul; 14(7):883-890. PubMed ID: 28673432
[TBL] [Abstract][Full Text] [Related]
6. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
8. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
Moisey R; Swinburne J; Orme S
Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
[TBL] [Abstract][Full Text] [Related]
9. Testosterone release rate and duration of action of testosterone pellet implants.
Kelleher S; Howe C; Conway AJ; Handelsman DJ
Clin Endocrinol (Oxf); 2004 Apr; 60(4):420-8. PubMed ID: 15049955
[TBL] [Abstract][Full Text] [Related]
10. 12-month observation of testosterone replacement effectiveness in a general population of men.
Miner MM; Bhattacharya RK; Blick G; Kushner H; Khera M
Postgrad Med; 2013 Mar; 125(2):8-18. PubMed ID: 23816767
[TBL] [Abstract][Full Text] [Related]
11. A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel(®)) insertion.
McCullough AR; Khera M; Goldstein I; Hellstrom WJ; Morgentaler A; Levine LA
J Sex Med; 2012 Feb; 9(2):594-601. PubMed ID: 22240203
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
13. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.
Jockenhövel F; Vogel E; Kreutzer M; Reinhardt W; Lederbogen S; Reinwein D
Clin Endocrinol (Oxf); 1996 Jul; 45(1):61-71. PubMed ID: 8796140
[TBL] [Abstract][Full Text] [Related]
15. Testosterone supplementation does not worsen lower urinary tract symptoms.
Pearl JA; Berhanu D; François N; Masson P; Zargaroff S; Cashy J; McVary KT
J Urol; 2013 Nov; 190(5):1828-33. PubMed ID: 23764078
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous testosterone pellet implant (Testopel) therapy for men with testosterone deficiency syndrome: a single-site retrospective safety analysis.
Cavender RK; Fairall M
J Sex Med; 2009 Nov; 6(11):3177-92. PubMed ID: 19796052
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
[TBL] [Abstract][Full Text] [Related]
18. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone.
Reyes-Vallejo L; Lazarou S; Morgentaler A
J Sex Med; 2007 Nov; 4(6):1757-62. PubMed ID: 17087806
[TBL] [Abstract][Full Text] [Related]
19. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
[TBL] [Abstract][Full Text] [Related]
20. A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism.
Kaminetsky JC; Moclair B; Hemani M; Sand M
J Sex Med; 2011 Apr; 8(4):1186-96. PubMed ID: 21269402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
